# TB-Bs1

Source: https://onco.cc/drugs/tb-bs1/  
OnCo record `tb-bs1` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TB-Bs1 is a bispecific antibody from Traverse Biotech that links T cells to tumour cells carrying ROR2, being developed for solid tumours.

## Summary

TB-Bs1 is the lead product on the pipeline page of Traverse Biotech: a CD3 by ROR2 bispecific antibody made on the DuoBody platform, for ROR2-positive solid tumours. The company cites published work on ROR2 as a cancer target. No clinical trial is registered.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Tags: pipeline
- Code: TB-Bs1
- Modality: Bispecific antibody (T-cell engager)
- Mechanism: Described by the company as a CD3 by ROR2 DuoBody bispecific antibody: one arm binds CD3 on T cells and the other ROR2 on tumour cells, bringing the two together.

## Sources

- Traverse Biotech pipeline: https://www.traversebiotech.com/pipeline-4-1

## Connected records

- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- companies: [Traverse Biotech](https://onco.cc/companies/traverse-biotech/)

---
JSON: https://onco.cc/api/v1/entities/tb-bs1.json